Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Similasan makes homeopathic eye drops and cold and allergy remedies and sells them to consumers and retailers in Switzerland and abroad.
Similasan is a Swiss maker of homeopathic medicines, and its best-known products are eye drops for dry, irritated, or allergy-stung eyes. It also sells remedies for colds and allergies — the kinds of little bottles and tubes people grab at a pharmacy when they want something gentle rather than a heavy-duty drug. The company sells these products to consumers through pharmacies and retailers, both in Switzerland and in export markets.
The business runs on a simple idea with a devoted following: tiny doses of natural ingredients, prepared in the homeopathic tradition, aimed at everyday annoyances rather than serious disease. Critics point out that homeopathy lacks strong scientific evidence that it works beyond a placebo, and regulators in some countries treat these products differently from conventional medicine. Similasan's customers, though, often want a mild option they can use often, and the brand's long history gives them confidence. Similasan was founded in 1980 in the Swiss town of Aarau, and it has spent decades building a niche most big drug companies ignore. Its name is Swiss, its packaging is pharmacy-shelf friendly, and its reputation travels — the company exports to a long list of countries, especially in Europe and North America. That international reach matters, because Switzerland alone is a small market.
The company is privately held, so it does not publish detailed financials the way a listed firm would, and it does not answer to stock market investors. Its strength is a trusted brand in a small, steady category; its vulnerability is that the category itself is contested by science and squeezed by regulators and larger competitors in the consumer health aisle. For a small Swiss firm, that has been a workable trade for more than four decades.
Saved answer · last researched 15 Nov 2026